FDA’s plan to boost biosimilar drugs could stall at the patent office

By Arthur Allen, KFF Health News While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say. Related Articles ICE courthouse arrests meet resistance from Democratic states Latino US citizens racially profiled by federal immigration agents in Chicago: ‘I felt like a piece of trash’ MAHA idealism meets political reality as RFK Jr. attempts to wrangle a growing movement Trump and Mamdani meet Friday in the Oval Office. They’ve cast each other as adversaries for months Schools fear disruptions as...